RE:Share price finally moving up ...but a long way to go before it gets into the right range.. Hopefully, a buck or two ( pre FDA approval) is around the corner... based on EBITDA multiples, need ( incl. for endotoxemic Covid patients) and the probabilities of Trial success.
With a highly infectious Omicron surge in US and short term presssure at the hospitals, I for one am not too worried about the Trial. Omicron will move through the population quickly ( see UK and SA) with less ICU strain. Then we can get on with full recruitment of patients as well as the Dialysis Study .
With regular and timely updates from the company we should see some sustained green.
MM